Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.
Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.
Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.
As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) reported its financial results for Q2 2021, with cash reserves of CAD 35.9 million expected to fund operations through 2022. The net loss widened to CAD 6.4 million, or CAD 0.12 per share, due to increased R&D costs, primarily for the MDNA11 program. The Phase 1/2 ABILITY Study for MDNA11 is set to initiate this Q3, targeting advanced solid tumors. Medicenna is also pursuing partnerships for MDNA55 and advancing its immunotherapy platforms. Preliminary safety and efficacy data from the ABILITY Study is anticipated by the end of 2022.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on August 13, 2021, at 8:30 AM ET to discuss its first quarter fiscal 2022 financial results and operational highlights. The company's focus is on immunotherapy, developing innovative IL-2, IL-4, and IL-13 Superkines as well as Empowered Superkines for cancer treatment. Notable assets include MDNA11, a next-generation IL-2 Superkine, and MDNA55, which has completed a Phase 2b trial for recurrent glioblastoma and has received FDA Fast-Track and Orphan Drug designations.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) has announced the initiation of a Phase 1/2 ABILITY Study to evaluate MDNA11, a novel IL-2 Superkine, in patients with advanced solid tumors. Enrollment is set to begin in Q3 2021 in Australia, with plans to expand to the US, UK, and Canada. The study will assess safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity through both monotherapy and combination trials. Preliminary results on safety and efficacy are expected by the end of 2021 and throughout 2022, respectively.
Medicenna Therapeutics announced promising preclinical data for MDNA109, showcasing its ability to significantly inhibit tumor growth in pancreatic cancer models. Published in Frontiers in Immunology, the study reveals MDNA109 promotes tumor regression and boosts survival rates while reshaping the tumor microenvironment. The oncolytic adenovirus carrying MDNA109 reprograms the environment from immunosuppressive to pro-inflammatory, enhancing immune response against tumors. The findings emphasize the potential of MDNA109 in treating difficult cancers like pancreatic cancer.
Medicenna Therapeutics announced the submission of a clinical trial application for its first-in-human ABILITY Study to evaluate MDNA11, a novel IL-2 super-agonist, in patients with advanced solid tumors. This Phase 1/2 trial aims to assess safety, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy. If approved, the trial is expected to initiate in Q3 2021, with preliminary results anticipated by year-end. Medicenna also plans to expand the study internationally, with hopes for a partnership regarding MDNA55 in the near future.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) reported its financial results for the fiscal year ending March 31, 2021. The company recorded a net loss of $17.3 million, or $0.35 per share, which represents an increase from the previous year's loss of $8.2 million. Medicenna has sufficient cash reserves of $40.4 million to fund operations into late 2022. Key developments include the planned Phase 1/2a trial for MDNA11 and continued progress on MDNA55 for recurrent glioblastoma. The management changes and strategic advancements position Medicenna for potential growth and clinical milestone achievements.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a conference call on May 28, 2021, at 8:30 AM ET to share financial results for the fiscal year ended March 31, 2021, alongside operational highlights. The call can be accessed via telephone or live webcast through the company's investor relations website. Medicenna specializes in immuno-oncology, focusing on novel IL-2, IL-4, and IL-13 Superkines, including MDNA11 and MDNA55, the latter having completed a Phase 2b trial for recurrent glioblastoma and received Fast-Track and Orphan Drug designations.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) has appointed Dr. Mann Muhsin as Chief Medical Officer. Dr. Muhsin brings over 20 years of experience in clinical trial design and execution, particularly in immuno-oncology. He has a strong background leading clinical programs for major pharmaceutical companies. His leadership is expected to advance MDNA11 through human trials and expand the company’s clinical pipeline. Medicenna focuses on innovative immunotherapies, particularly through their Superkine and BiSKITs™ platforms, presenting a promising outlook in cancer treatment.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced the publication of positive results from its Phase 2b trial for MDNA55, an innovative treatment for recurrent glioblastoma (rGBM), in Clinical Cancer Research. The study shows a median overall survival (OS) of 11.8 months, exceeding standard treatments. Notably, the tumor control rate is 81%. The FDA has approved a hybrid Phase 3 design leveraging an external control arm, aiming for regulatory approval. The findings suggest that early progression-free survival (PFS) could predict OS effectively, enhancing prospects for the upcoming Phase 3 trial.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the appointment of Dr. Kevin Moulder as Chief Scientific Officer. Dr. Moulder brings over 30 years of experience in drug discovery in oncology and immunology. His expertise is expected to enhance the development of Medicenna's Superkine and BiSKITs™ platforms. Dr. Moulder expressed excitement about advancing these promising immunotherapy assets, which aim to address limitations in current treatments. Medicenna's lead asset, MDNA55, has completed a Phase 2b trial for rGBM and holds FDA Fast-Track and Orphan Drug status.
FAQ
What does Medicenna Therapeutics specialize in?
What are superkines?
How does Medicenna's T-MASK platform work?
What are empowered cytokines (ECs)?
What recent achievements has Medicenna made?
What is the company's mission?
How does Medicenna ensure the safety of its treatments?
What are immunocytokines?
How does Medicenna collaborate with other researchers?
What is the financial outlook for Medicenna?
